TSRO - Tesaro, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
37.48
+1.71 (+4.78%)
As of 12:28PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close35.77
Open35.75
Bid37.52 x 900
Ask37.59 x 800
Day's Range35.75 - 37.84
52 Week Range25.62 - 129.64
Volume740,337
Avg. Volume2,107,407
Market Cap2.058B
Beta0.93
PE Ratio (TTM)N/A
EPS (TTM)-9.85
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est55.40
Trade prices are not sourced from all markets
  • Options Traders Expect Huge Moves in Tesaro (TSRO) Stock
    Zacks2 days ago

    Options Traders Expect Huge Moves in Tesaro (TSRO) Stock

    Investors need to pay close attention to Tesaro (TSRO) stock based on the movements in the options market lately.

  • How Tesaro Hopes to Tackle Lung Cancer
    Motley Fool12 days ago

    How Tesaro Hopes to Tackle Lung Cancer

    The company is advancing a research program that it hopes will improve outcomes for patients with non-small cell lung cancer.

  • Tesaro (TSRO) Surges: Stock Moves 5.5% Higher
    Zacks13 days ago

    Tesaro (TSRO) Surges: Stock Moves 5.5% Higher

    Tesaro (TSRO) shares rose nearly 6% in the last trading session, amid huge volumes.

  • Investor's Business Daily14 days ago

    This Biotech Got A Bullish Pop On Its Experimental Cancer Regimen

    Tesaro stock popped in bullish fashion Wednesday after the biotech reported an experimental regimen was successful in 64% of lung cancer patients tested.

  • Here’s Why Tesaro Stock Is on the Rise Today
    Market Realist14 days ago

    Here’s Why Tesaro Stock Is on the Rise Today

    Today, Tesaro (TSRO) announced the start of the second stage of its JASPER trial. Tesaro is conducting the Phase 2 JASPER trial to evaluate the safety and efficacy of Zejula and an anti-PD-1 antibody combination therapy for the treatment of individuals with NSCLC (non-small cell lung cancer) in a first-line setting. Tesaro decided to go ahead with the trial after Zejula achieved the protocol specified response criteria in the initial group of 16 patients, among whom 14 were evaluable.

  • European Commission Approves Puma Biotechnology’s Nerlynx
    Market Realist14 days ago

    European Commission Approves Puma Biotechnology’s Nerlynx

    On September 4, the European Commission approved the marketing authorization of Puma Biotechnology’s Nerlynx as extended adjuvant therapy for the treatment of adults with early-stage HER2-positive (hormone receptor-2 positive) breast cancer who completed previous adjuvant trastuzumab-containing therapy less than a year ago.

  • GlobeNewswire15 days ago

    TESARO Announces Expansion to Second Stage of JASPER Trial of ZEJULA® in Combination With TSR-042 in Non-Small Cell Lung Cancer

    TESARO, Inc. (TSRO), an oncology-focused biopharmaceutical company, today announced it has initiated the second stage of the JASPER study that is designed to assess clinical benefit of ZEJULA® in combination with an anti-PD-1 antibody in first-line non-small cell lung cancer (NSCLC) patients. “These JASPER data provide preliminary evidence that the combination of ZEJULA and an anti-PD-1 antibody could be active as a first-line treatment for patients with non-small cell lung cancer and high levels of PD-L1 expression,” said Mary Lynne Hedley, Ph.D., President and COO of TESARO.

  • See what the IHS Markit Score report has to say about TESARO Inc.
    Markit15 days ago

    See what the IHS Markit Score report has to say about TESARO Inc.

    TESARO Inc NASDAQ/NGS:TSRO

  • See what the IHS Markit Score report has to say about TESARO Inc.
    Markit18 days ago

    See what the IHS Markit Score report has to say about TESARO Inc.

    TESARO Inc NASDAQ/NGS:TSRO

  • Why Insys Therapeutics Stock Rose ~34% Yesterday
    Market Realist19 days ago

    Why Insys Therapeutics Stock Rose ~34% Yesterday

    On August 30, Insys Therapeutics (INSY) stock closed at $10.67, a ~34.05% increase from the previous day’s close of $7.96. On August 29, Insys Therapeutics stock closed at $7.96, which was ~94% above its 52-week low of $4.10 on October 31, 2017. Its closing price on August 30 was 31% below its 52-week high of $14.00 on January 3, 2018.

  • GlobeNewswire23 days ago

    TESARO Announces Participation at Three Investor Conferences

    WALTHAM, Mass., Aug. 27, 2018-- TESARO, Inc., an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences. Citi’ s 13 th Annual Biotech Day at ...

  • See what the IHS Markit Score report has to say about TESARO Inc.
    Markit25 days ago

    See what the IHS Markit Score report has to say about TESARO Inc.

    TESARO Inc NASDAQ/NGS:TSRO

  • Here’s What Tesaro’s Valuation Trend Indicates
    Market Realistlast month

    Here’s What Tesaro’s Valuation Trend Indicates

    Tesaro’s (TSRO) Phase 3 PRIMA trial of Zejula to evaluate it for the treatment of women with newly diagnosed ovarian cancer, irrespective of BRCA mutation status, has been completely enrolled. Its Phase 2 trial of Zejula in combination with an anti-PD-1 antibody in first-line non-small cell lung cancer is ongoing. The company expects to present data in the first half of 2019. In its immuno-oncology pipeline, Tesaro plans to submit a BLA (Biologic License Application) for TSR-042 in 2019.

  • A Look at Tesaro’s Revenue Trends
    Market Realistlast month

    A Look at Tesaro’s Revenue Trends

    Tesaro (TSRO) generated total revenues of $57.21 million in the second quarter. The company generates revenues from product sales and licensing and collaboration activities. Its product sales are comprised of Zejula and Varubi sales.

  • Understanding Tesaro’s Operational Performance
    Market Realistlast month

    Understanding Tesaro’s Operational Performance

    Tesaro’s (TSRO) selling, general, and administrative expenses increased from $92.98 million in the second quarter of 2017 to $100.03 million in the second quarter of 2018. The increase was due to higher expenses for salaries, benefits, and other personnel-related costs.

  • Analysts’ Expectations for Tesaro and Its Peers in August
    Market Realistlast month

    Analysts’ Expectations for Tesaro and Its Peers in August

    Tesaro (TSRO) is a commercial-stage biopharmaceutical company primarily focused on developing treatments for solid tumors by using small molecules and immune-oncology antibodies both as monotherapies and in combinations. Tesaro’s key product, Zejula, has been approved in the United States as well as the European Union as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Tesaro commercialized Zejula in the United States in April 2017 and in Europe in December 2017.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of TSRO earnings conference call or presentation 2-Aug-18 8:15pm GMT

    Q2 2018 TESARO Inc Earnings Call

  • Is the Options Market Predicting a Spike in Tesaro (TSRO) Stock?
    Zackslast month

    Is the Options Market Predicting a Spike in Tesaro (TSRO) Stock?

    Investors need to pay close attention to Tesaro (TSRO) stock based on the movements in the options market lately.

  • Tesaro: Lower Fiscal 2018 Guidance, Share Price Fell on August 3
    Market Realistlast month

    Tesaro: Lower Fiscal 2018 Guidance, Share Price Fell on August 3

    On August 2, Tesaro (TSRO) reported revenues of ~$57.2 million in the second quarter, which is a rise of ~94.2% YoY (year-over-year). The increase was driven by rising demand for ZEJULA, which reported sales of $54 million in the second quarter. The sales were ~107.7% higher on a YoY basis and 10% higher on a sequential basis. For fiscal 2018, Tesaro expects ZEJULA, which is a leading PARP inhibitor in ovarian cancer indication, to report revenues of $225 million–$235 million. Based on the midpoint of the guidance range, the revenue guidance implies YoY growth of ~111% and sequential growth of 10% for ZEJULA.

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Tesaro and Stericycle

    NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Medical companies Tesaro and Stericycle reported second quarter results last week that sent both stocks tumbling into the red. Both companies lowered their ...

  • Why Shake Shack, Tesaro, and Square Slumped Today
    Motley Fool2 months ago

    Why Shake Shack, Tesaro, and Square Slumped Today

    Find out how poor earnings hit some of these companies hard.

  • Investor's Business Daily2 months ago

    Tesaro CEO Says Its Drug 'Will Get There' — Analysts Strongly Disagree

    Tesaro stock crashed to a four-year low Friday after the biotech cut its 2018 outlook and analysts suggested its key drug, Zejula, is struggling to gain traction in the U.S.

  • A Disappointment Is Sinking Tesaro Shares Today
    Motley Fool2 months ago

    A Disappointment Is Sinking Tesaro Shares Today

    The commercial-stage biotech has offered up a less-than-optimistic outlook.

  • MarketWatch2 months ago

    Tesaro stock drops 16% on worse-than-expected Q2 results, downbeat guidance

    Tesaro Inc. (TSRO) shares dropped 16.3% in extremely heavy Friday morning trade after the company reported a larger-than-expected second-quarter loss and revenue miss, along with downbeat 2018 guidance. The FactSet adjusted earnings-per-share consensus was a loss of $2.63. Revenue rose to $57.21 million from $29.46 million, below the FactSet consensus of $65.5 million.

  • TESARO (TSRO) Misses Earnings and Revenue Estimates in Q2
    Zacks2 months ago

    TESARO (TSRO) Misses Earnings and Revenue Estimates in Q2

    TESARO (TSRO) misses estimates for both earnings and revenues in the second quarter but beats on revenues. Zejula sales increase.